Gut Microbiome and Metabolite Profiles Linked to Albuminuria in Type 2 Diabetes
Overview
This study analyzed gut microbiome species and plasma metabolites in 752 individuals with type 2 diabetes, identifying three microbial species associated with albuminuria. The findings were replicated in a larger prediabetic cohort, highlighting specific metabolites potentially involved in albuminuria progression.
Background
Type 2 diabetes is associated with serious complications including diabetic nephropathy, for which albuminuria is an important early marker. The gut microbiome has been implicated in the development of albuminuria, possibly through microbial metabolites influencing kidney function. Previous studies lacked high-resolution microbiome data and metabolite profiling, leaving gaps in understanding the microbiome-metabolite-albuminuria relationship. This study employed deep shotgun metagenomic sequencing and plasma metabolomics to explore these associations in a large, well-characterized cohort.
Three gut microbial species were significantly associated with albuminuria in type 2 diabetes patients.
Two of these species were validated in an independent prediabetic population, supporting their relevance.
Thirty-six plasma metabolites correlated with the albuminuria-associated microbial species, indicating functional metabolic links.
Functional mapping implicated microbial regulation of imidazole propionate and trigonelline metabolites, previously linked to albuminuria progression.
The study utilized deep shotgun metagenomic sequencing, providing high taxonomic resolution and functional insights.
Clinical Implications
These findings suggest that specific gut microbial species and their metabolites may serve as biomarkers or therapeutic targets for early kidney damage in type 2 diabetes. Monitoring and potentially modulating the gut microbiome could complement existing strategies to prevent or slow albuminuria progression. Further research is warranted to explore causality and intervention approaches.
Conclusion
This study advances understanding of the complex interplay between the gut microbiome, circulating metabolites, and albuminuria in type 2 diabetes, highlighting microbial species and metabolites that may influence kidney disease progression.
References
SCAPIS Study Group 2013-2018 -- Swedish CArdioPulmonary BioImage Study
by Yi-Ting Lin, Sergi Sayols-Baixeras, Tiscar Graells, Koen F Dekkers, Gabriel Baldanzi, Diem Nguyen, Anders Larsson, Tobias Rudholm Feldreich, Nynne Nielsen, Aron C Eklund, Jacob B Holm, H Bjørn Nielsen, Göran Bergström, J Gustav Smith, Andrei Malinovschi, Gunnar Engström, Marju Orho-Melander, Tove Fall, Johan Ärnlöv
A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.
